Compare Bumble Inc (BMBL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumble Inc vs Neurocrine Biosciences Inc — how do they compare? Bumble Inc trades at $2.82 (market cap $366.87M), while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 44.9× Bumble Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| BMBL | NBIX | |
|---|---|---|
Market Cap | $366.87M | $16.46B |
Sector | Technology | Health |
52-Week High | $7.17 | $185.50 |
52-Week Low | $2.70 | $123.10 |
Enterprise Value | $672.73M | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMBL trades at $2.73, down 3.53% on the day, with a bearish technical outlook. The company reported a Q2 2026 earnings miss and negative net income margin of -57.96%, though revenue of $965.66M in 2025 shows scale. Recent news highlights a major shift in its women-first messaging policy to boost engagement amid slowing growth and exploration of a potential sale.
The outlook is challenged by persistent losses and declining paying users, but a low P/S of 0.38 offers valuation appeal. Risks include execution of product changes and intense competition. Analysts are mostly neutral with a $3.62 price target, suggesting cautious optimism if turnaround efforts succeed.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
